SCHEMBL21085388

SCHEMBL21085388

CC1C(=O)C(C#N)=CC2(C)C3=CC(=O)C4C(CCC5(C(=O)O)CCC(C)(C)CC45)C3(C)CCC12

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 9/20 0.51
▸ KEAP1 Q14145 1/20 0.51
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ MBOAT4 Q96T53 4/20 0.42
▸ USP2 O75604 1/20 0.41
▸ STAT3 P40763 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41
▸ USP7 Q93009 1/20 0.41
▸ RORC P51449 6/20 0.41
▸ CCR6 P51684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21085846 0.91 MBOAT4 (0.45) NOS2KEAP1CYP3A4CYP2C9CYP2C19
SCHEMBL21022880 0.91 MBOAT4 (0.53) NOS2KEAP1CYP3A4CYP2C9CYP2C19
SCHEMBL21085842 0.91 MBOAT4 (0.53) NOS2KEAP1CYP3A4CYP2C9CYP2C19
SCHEMBL20826041 0.91 MBOAT4 (0.53) NOS2KEAP1CYP3A4CYP2C9CYP2C19
SCHEMBL21573987 0.91 MBOAT4 (0.53) NOS2KEAP1CYP3A4CYP2C9CYP2C19
SCHEMBL23098149 0.91 NOS2 (0.41) NOS2KEAP1CYP3A4CYP2C9CYP2C19
SCHEMBL24035439 0.90 CYP3A4 (0.43) NOS2KEAP1CYP3A4CYP2C9CYP2C19
SCHEMBL21085475 0.89 MBOAT4 (0.55) NOS2KEAP1CYP3A4CYP2C9CYP2C19
SCHEMBL20925754 0.87 CYP3A4 (0.41) NOS2KEAP1CYP3A4CYP2C9CYP2C19
SCHEMBL20925948 0.87 NOS2 (0.50) NOS2KEAP1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021104391-A1 OLEANANE CINNAMAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 鲁南制药集团股份有限公司 2021-06-03 — — WO disclosed
EP-3492077-A1 SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE Reata Pharmaceuticals, Inc. (US) 2019-06-05 — — EP disclosed
Send feedback